Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007)

Katai, Hitoshi; Ishikawa, Takashi; Akazawa, Kohei; Isobe, Yoh; Miyashiro, Isao; Oda, Ichiro; Tsujitani, Shunichi; Ono, Hiroyuki; Tanabe, Satoshi; Fukagawa, Takeo; Nunobe, Souya; Kakeji, Yoshihiro; Nashimoto, Atsushi

doi:10.1007/s10120-017-0716-7

Cited by 370 publications

(271 citation statements)

References 11 publications

Supporting

Mentioning

255

Contrasting

Unclassified

Order By: Relevance

“…Those gastric cancers without distinct mucosa may present as gastric wall thickening, and can fortunately be easily detected by TUS-OCCA during population-based mass screening. Katai et al [33] showed that the 5-year overall survival rates of gastric cancers with pathological stage IA, IB, II, IIIA, IIIB, and IV disease were 91.5, 83.6, 70.6, 53.6, 34.8, and 16.4%, respectively. The prognosis of gastric cancer is better if the gastric cancer could be detected earlier during population-based mass screening per year.…”

Section: Discussionmentioning

confidence: 99%

Preliminary opinion on assessment categories of stomach ultrasound report and data system (Su-RADS)

et al. 2018

View full text Add to dashboard Cite

ObjectiveTransabdominal ultrasound after oral administration of an echoic cellulose-based gastric ultrasound contrast agent (TUS-OCCA) has recently been suggested as a valuable mass-screening tool for gastric cancer. The aim of this study was to propose a producible stomach ultrasound reporting and data system (Su-RADS) using TUS-OCCA for gastric cancer screening.PatientsThe study includes information of 2738 patients who underwent both gastroscopy and TUS-OCCA examinations recorded in software system. Gastroscopy examination with pathological diagnosis was considered as gold standard. Various gastric lesions were classified into category 1–5 based on gastric wall thicknesses of them (especially the mucosa layer).ResultsThe total malignant ratios of patients enrolled in this study were 17.1% (469/2738). The malignant ratios for category 1–5 were, respectively, 1.1, 1.7, 12.2, 34.2 and 78.1%. Category 2 indicated mild thickening of gastric wall at low risk for malignancy (1.7%); category 3 indicated moderate thickening at moderate risk for malignancy (12.2%); category 4 indicated severe thickening at high risk for malignancy (34.2%); category 5 indicated extremely severe thickening at extremely high risk for malignancy (78.1%). If category 2 was identified as cut-off point distinguishing between benign and malignant, the sensitivity and specificity by Su-RADS are 95.1 and 78.6%, respectively.ConclusionThe Su-RADS system could inform the physicians about key findings, indicating the risk for malignancy and necessity of additional gastroscopy examination. Prospectively randomly controlled study design with larger clinical trial is needed for further investigations.Electronic supplementary materialThe online version of this article (10.1007/s10120-018-0798-x) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Preliminary opinion on assessment categories of stomach ultrasound report and data system (Su-RADS)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Despite various treatments such as surgical resection combined with chemotherapy, the prognosis for patients with advanced GC remains poor. The 5‐year overall survival rates of patients with pathological stage IV disease who underwent resection between 2001 and 2007 is 16.4% in Japan . Previous studies have reported that PD‐L1 is expressed in 42% of GC tissue, and is correlated with tumor size, invasion, lymph node status and patient survival .…”

Section: Introductionmentioning

confidence: 99%

PD‐L1 expression is mainly regulated by interferon gamma associated with JAK‐STAT pathway in gastric cancer

et al. 2017

View full text Add to dashboard Cite

Despite multidisciplinary treatment for patients with advanced gastric cancer, their prognosis remains poor. Therefore, the development of novel therapeutic strategies is urgently needed, and immunotherapy utilizing anti‐programmed death 1/‐programmed death ligand‐1 mAb is an attractive approach. However, as there is limited information on how programmed death ligand‐1 is upregulated on tumor cells within the tumor microenvironment, we examined the mechanism of programmed death ligand‐1 regulation with a particular focus on interferon gamma in an in vitro setting and in clinical samples. Our in vitro findings showed that interferon gamma upregulated programmed death ligand‐1 expression on solid tumor cells through the JAK‐signal transducer and activator of transcription pathway, and impaired the cytotoxicity of tumor antigen‐specific CTL against tumor cells. Following treatment of cells with anti‐programmed death ligand‐1 mAb after interferon gamma‐pre‐treatment, the reduced anti‐tumor CTL activity by interferon gamma reached a higher level than the non‐treatment control targets. In contrast, programmed death ligand‐1 expression on tumor cells also significantly correlated with epithelial‐mesenchymal transition phenotype in a panel of solid tumor cells. In clinical gastric cancer samples, tumor membrane programmed death ligand‐1 expression significantly positively correlated with the presence of CD8‐positive T cells in the stroma and interferon gamma expression in the tumor. The results suggest that gastric cancer patients with high CD8‐positive T‐cell infiltration may be more responsive to anti‐programmed death 1/‐programmed death ligand‐1 mAb therapy.

show abstract

“…However, both studies had methodology issues, such as a mixture of tumors with different biological behaviors (esophagus, esophagus‐gastric junction [EGJ] and stomach) and inadequate lymphadenectomy. When compared with specialized centers worldwide, both groups from these studies had low survival rates 5,8‐10 . Additionally, Schuhmacher et al 11 failed to demonstrate the benefit of NACT vs D2‐gastrectomy alone.…”

Section: Introductionmentioning

confidence: 99%

Impact of neoadjuvant chemotherapy on surgical and pathological results of gastric cancer patients: A case‐control study

Charruf

Ramos

Pereira

et al. 2020

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objective Neoadjuvant chemotherapy (NACT) followed by radical surgery represents a treatment option for patients with advanced gastric cancer (GC). This case‐control study aimed to evaluate the clinicopathological characteristics and surgical outcomes of GC patients who received NACT, and its impact on survival. Methods We retrospectively reviewed all patients with GC who underwent gastrectomy. A total of 45 cases with NACT were matched with consecutive 45 patients who underwent upfront gastrectomy for the following characteristics: gender, age, gastrectomy type, lymphadenectomy extent, American Society of Anesthesiologists class, histological type, cT and cN. Results NACT group had smaller tumors (4.9 vs 6.8 cm P = .006), lower lymphatic invasion rate (40% vs 73.3%, P = .001), lower venous invasion rate (18% vs 46.7%, P = .003) and lower perineural invasion rate (35% vs 77.8%, P < .0001). The ypTNM stage was lower in patients treated with NACT (P < .001). The major postoperative complication (POC) rate was lower in NACT patients (6.7% vs 24.4%, P = .02), as was hospital length of stay (10.8 vs 17 days, P = .005). Conclusions NACT allowed nodal and tumor downstaging. In addition, patients who underwent NACT had fewer POC and shorter length of hospital stay.

show abstract

Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007)

Abstract: Detailed analyses of the data from more than 100,000 patients show the recent trends of the outcomes of gastric cancer treatment in Japan and provide baseline information for use by medical communities around world.

Cited by 370 publications

References 11 publications

Preliminary opinion on assessment categories of stomach ultrasound report and data system (Su-RADS)

Preliminary opinion on assessment categories of stomach ultrasound report and data system (Su-RADS)

PD‐L1 expression is mainly regulated by interferon gamma associated with JAK‐STAT pathway in gastric cancer

Impact of neoadjuvant chemotherapy on surgical and pathological results of gastric cancer patients: A case‐control study

Contact Info

Product

Resources

About